Last reviewed · How we verify
MANNOSULFAN
MANNOSULFAN is a mannosulfan drug. It is currently in Phase 2 development.
Mannosulfan is thought to work by interacting with a specific biological target, although the exact nature of this interaction is not yet understood.
Mannosulfan is a small molecule with a verified status in a clinical study (NCT06899321) for skin brightening and pain conditions. It was tested as part of cosmetic products M68, Z15, and R52 in a 6-week study.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MANNOSULFAN |
|---|---|
| Drug class | mannosulfan |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like locks, and mannosulfan is a key that fits into one of those locks. When it binds to the lock, it can either turn it on or off, depending on the type of lock and the key's shape. This can help regulate various bodily processes, but more research is needed to understand how mannosulfan works and what effects it has on the body.
Approved indications
Common side effects
Key clinical trials
- The Effect of Cosmetic Products on Skin Brightening (NA)
- Long-term Opioid Therapy, Misuse and Mortality in Patients With Chronic Non-cancer Pain in Germany
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MANNOSULFAN CI brief — competitive landscape report
- MANNOSULFAN updates RSS · CI watch RSS
Frequently asked questions about MANNOSULFAN
What is MANNOSULFAN?
How does MANNOSULFAN work?
What drug class is MANNOSULFAN in?
What development phase is MANNOSULFAN in?
Related
- Drug class: All mannosulfan drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing